Radioimmunotherapy of malignancy using antibody targeted radionuclides.

Antibodies directed against tumour associated antigens provide a means for delivering preferentially cytotoxic radionuclides to the cells of primary and secondary tumours. The factors that influence the effectiveness of the radiation in the tumour compared with its effect on the radiosensitive normal tissues include the specificity of the antibody, the distribution of targeted energy within the tumour and the host's response to the injected foreign antibody. Recently some encouraging results from clinical trials of radioimmunotherapy have been reported in the literature. There is a continual search for more avid and specific antibodies, and the techniques of genetic engineering are being applied to the problem of reducing the antigenicity and mass of the carrier antibody. The improved efficiency of the labelled antibody needs to be supplemented by an identification of those tumours most likely to respond to this form of therapy.

[1]  A. Houghton,et al.  Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient. Implications for the study of tumor antigens , 1981, The Journal of experimental medicine.

[2]  S. Pestka,et al.  Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte alpha-interferon treatment. , 1984, Cancer research.

[3]  D. Ettinger,et al.  Comparative tumor dose from 131I-labeled polyclonal anti-ferritin, anti-AFP, and anti-CEA in primary liver cancers. , 1984, Cancer drug delivery.

[4]  H. Waldmann,et al.  Therapeutic potential of monovalent monoclonal antibodies , 1984, Nature.

[5]  S. Stewart,et al.  Antibody-guided irradiation of malignant pleural and pericardial effusions. , 1986, British journal of cancer.

[6]  P. Hand,et al.  Biological behavior of human breast carcinoma-associated antigens expressed during cellular proliferation. , 1983, Cancer research.

[7]  R. Warnke,et al.  A clinical trial of anti-idiotype therapy for B cell malignancy. , 1985, Blood.

[8]  E. Kim,et al.  Circulating immune complexes in cancer patients receiving goat radiolocalizing antibodies to carcinoembryonic antigen. , 1980, Cancer research.

[9]  P. Hand,et al.  Definition of antigenic heterogeneity and modulation among human mammary carcinoma cell populations using monoclonal antibodies to tumor-associated antigens. , 1983, Cancer research.

[10]  F. Stevenson,et al.  Preliminary experience in treating lymphocytic leukaemia with antibody to immunoglobulin idiotypes on the cell surfaces. , 1980, British Journal of Cancer.

[11]  A. Vaughan,et al.  The in vivo fate of a 211At labelled monoclonal antibody with known specificity in a murine system. , 1982, International journal of radiation oncology, biology, physics.

[12]  D. Kufe,et al.  Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. , 1980, Cancer research.

[13]  M. Ling,et al.  A model system that predicts effective half-life for radiolabeled antibody therapy. , 1985, International journal of radiation oncology, biology, physics.

[14]  L. Feinendegen.  Biological damage from the Auger effect, possible benefits , 1975, Radiation and environmental biophysics.

[15]  D. Ettinger,et al.  Use of isotopic immunoglobulin in therapy. , 1980, Cancer research.

[16]  S. Burchiel,et al.  Heterogeneity of HLA-A,B, Ia-like, and melanoma-associated antigen expression by human melanoma cell lines analyzed with monoclonal antibodies and flow cytometry. , 1982, Cancer research.

[17]  K. Sikora,et al.  Tumour localisation by human monoclonal antibodies , 1985, Medical oncology and tumor pharmacotherapy.

[18]  M. Lichtenstein,et al.  Tumor immunotherapy in the mouse with the use of 131I-labeled monoclonal antibodies. , 1984, Journal of the National Cancer Institute.

[19]  S. Larson,et al.  Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy. , 1983, The Journal of clinical investigation.

[20]  P. Edwards,et al.  Antigenic heterogeneity of breast cell lines detected by monoclonal antibodies and its relationship with the cell cycle. , 1985, Journal of cell science.

[21]  K. Hofer.  Radiation biology and potential therapeutic applications of radionuclides. , 1980, Bulletin du cancer.

[22]  S. Ferrone,et al.  Antigenic heterogeneity of surgically removed primary and autologous metastatic human melanoma lesions. , 1983, Journal of immunology.

[23]  P. Schellhammer,et al.  Immunohistochemical localization of prostate carcinoma-associated antigens. , 1983, Cancer research.

[24]  D. Ettinger,et al.  Phase I-II study of isotopic immunoglobulin therapy for primary liver cancer. , 1982, Cancer treatment reports.

[25]  D. Ettinger,et al.  Dosimetry of 131I-labeled antiferritin in hepatoma: specific activities in the tumor and liver. , 1983, Cancer treatment reports.

[26]  R. Dillman,et al.  Lack of radioimmunodetection and complications associated with monoclonal anticarcinoembryonic antigen antibody cross-reactivity with an antigen on circulating cells. , 1984, Cancer research.

[27]  C. Milstein,et al.  Attempted targeting of a monoclonal antibody in a human tumour xenograft system. , 1981, European journal of cancer & clinical oncology.

[28]  J. Minna,et al.  Heterogeneity of cell surface antigen expression of human small cell lung cancer detected by monoclonal antibodies. , 1986, Cancer research.

[29]  D. Ettinger,et al.  Isotopic immunoglobulin in an integrated multimodal treatment program for a primary liver cancer: a case report. , 1979, Cancer treatment reports.

[30]  G. Mariani,et al.  Imaging with 131I-labeled monoclonal antibodies to a high-molecular-weight melanoma-associated antigen in patients with melanoma: efficacy of whole immunoglobulin and its F(ab')2 fragments. , 1985, Cancer research.

[31]  T. Waldmann,et al.  Bismuth-212-labeled anti-Tac monoclonal antibody: alpha-particle-emitting radionuclides as modalities for radioimmunotherapy. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[32]  A. V. Peterson,et al.  Experimental radiotherapy of murine lymphoma with 131I-labeled anti-Thy 1.1 monoclonal antibody. , 1985, Cancer research.

[33]  S. Order,et al.  Antiferritin IgG antibody for isotopic cancer therapy. , 1981, Oncology.

[34]  S. Hellman.  Iodine 131 antiferritin, a new treatment modality in hepatoma: a Radiation Therapy Oncology Group study. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  A. Epenetos,et al.  Antibody guided irradiation of brain glioma by arterial infusion of radioactive monoclonal antibody against epidermal growth factor receptor and blood group A antigen. , 1985, British medical journal.

[36]  D. Ettinger,et al.  Phase I-II study of radiolabeled antibody integrated in the treatment of primary hepatic malignancies. , 1979, International journal of radiation oncology, biology, physics.

[37]  R. Ludatscher,et al.  Ultrastructural observations on the capillaries of human thyroid tumours , 1979, The Journal of pathology.

[38]  A. Hirano,et al.  Fenestrated blood vessels in a metastatic renal carcinoma in the brain. , 1972, Laboratory investigation; a journal of technical methods and pathology.

[39]  B. Sahagan,et al.  A genetically engineered murine/human chimeric antibody retains specificity for human tumor-associated antigen. , 1986, Journal of immunology.

[40]  S. Order,et al.  Distribution of and physiologic factors that affect 131I-antiferritin tumor localization in experimental hepatoma. , 1984, International journal of radiation oncology, biology, physics.

[41]  A. Sinha,et al.  Specific immunosuppression by immunotoxins containing daunomycin. , 1986, Science.

[42]  P. Doherty,et al.  DTPA-coupled antibodies labeled with yttrium-90. , 1985, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[43]  R. Jewkes,et al.  LIPOSOMALLY ENTRAPPED SECOND ANTIBODY IMPROVES TUMOUR IMAGING WITH RADIOLABELLED (FIRST) ANTITUMOUR ANTIBODY , 1982, The Lancet.

[44]  P. Alderson,et al.  Potential of palladium-109-labeled antimelanoma monoclonal antibody for tumor therapy. , 1984, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[45]  R. F. Martin.  Induction of double-stranded breaks in DNA by binding with an 125i-labelled acridine. , 1977, International journal of radiation biology and related studies in physics, chemistry, and medicine.

[46]  S. Larson,et al.  Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments. , 1984, Cancer treatment reports.

[47]  M. Glennie,et al.  Univalent antibodies kill tumour cells in vitro and in vivo , 1982, Nature.

[48]  A. Harrison,et al.  Preparation of a 211At-IgG conjugate which is stable in vivo. , 1984, The International journal of applied radiation and isotopes.

[49]  L. Feinendegen,et al.  Inactivation of Mammalian Cells after Disintegrations of 3H or 125I in Cell DNA at −196°C , 1973 .

[50]  H. Liber,et al.  Toxicity and mutagenicity of X-rays and [125I]dUrd or [3H]TdR incorporated in the DNA of human lymphoblast cells. , 1983, Mutation research.